BioSpace News Archive

Business

MagForce AG Publishes Financial Results for the First Half of 2018 and Operative Highlights

Start of pivotal US prostate cancer study and treatment of first patients with NanoTherm therapy following U.S. FDA IDE approval in February and IRB approvals in April of this year

October 30, 2018
·
8 min read
Combioxin Highlights Results from Successful CAL02-001 First-in-Human Trial Evaluating CAL02 in Severe Pneumonia at ESICM 2018

Combioxin SA announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.

October 30, 2018
·
4 min read
Business

Zelluna Immunotherapy appoints Geir Christian Melen as Chief Financial Officer

Appointment to strengthen Zelluna’s financial and operational capabilities

October 30, 2018
·
2 min read
Business

GENFIT: Third quarter 2018 financial information (Unaudited financial information under IFRS)

Cash and cash equivalents of €219.9 million at September 30, 2018

October 30, 2018
·
3 min read
Drug Development

GeoVax Announces Further Positive Results of its HIV Preventive Vaccine Program at International HIV Research Conference

Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response

October 30, 2018
·
6 min read
Drug Development

Topline interim results of FALCON trial Part 1 in CF

Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).

October 30, 2018
·
5 min read
NOXXON TO ATTEND EUROPEAN INVESTOR AND PARTNERING CONFERENCES IN NOVEMBER 2018

NOXXON Pharma N.V. announced today that the company will attend the BIO-Europe Conference and the Salon Actionaria in November 2018.

October 30, 2018
·
2 min read
FDA

Medtronic Receives FDA Approval for Valiant Navion(TM) Thoracic Stent Graft System

Next-Generation Thoracic Endovascular Repair (TEVAR) Device Expands Applicability to Broader Range of Patients

October 30, 2018
·
4 min read
Policy

Promore Pharma has had a successful meeting with the FDA regarding PXL01

Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that that it has had a successful meeting with the US Food and Drug Administration (FDA) regarding the continued development of PXL01.

October 30, 2018
·
4 min read
Racial differences in colorectal cancer incidence not due to biology

Higher rates in blacks appear to be linked to access to screening

October 30, 2018
·
3 min read